全文获取类型
收费全文 | 9528篇 |
免费 | 578篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 312篇 |
妇产科学 | 230篇 |
基础医学 | 1378篇 |
口腔科学 | 364篇 |
临床医学 | 1002篇 |
内科学 | 2076篇 |
皮肤病学 | 179篇 |
神经病学 | 1040篇 |
特种医学 | 203篇 |
外科学 | 731篇 |
综合类 | 40篇 |
一般理论 | 3篇 |
预防医学 | 780篇 |
眼科学 | 152篇 |
药学 | 684篇 |
中国医学 | 14篇 |
肿瘤学 | 911篇 |
出版年
2023年 | 88篇 |
2022年 | 90篇 |
2021年 | 293篇 |
2020年 | 216篇 |
2019年 | 232篇 |
2018年 | 287篇 |
2017年 | 217篇 |
2016年 | 271篇 |
2015年 | 305篇 |
2014年 | 423篇 |
2013年 | 553篇 |
2012年 | 748篇 |
2011年 | 791篇 |
2010年 | 400篇 |
2009年 | 362篇 |
2008年 | 640篇 |
2007年 | 690篇 |
2006年 | 642篇 |
2005年 | 553篇 |
2004年 | 533篇 |
2003年 | 483篇 |
2002年 | 477篇 |
2001年 | 55篇 |
2000年 | 41篇 |
1999年 | 58篇 |
1998年 | 67篇 |
1997年 | 60篇 |
1996年 | 39篇 |
1995年 | 58篇 |
1994年 | 43篇 |
1993年 | 30篇 |
1992年 | 30篇 |
1991年 | 33篇 |
1990年 | 21篇 |
1989年 | 37篇 |
1988年 | 13篇 |
1987年 | 12篇 |
1986年 | 21篇 |
1985年 | 21篇 |
1984年 | 27篇 |
1983年 | 30篇 |
1982年 | 21篇 |
1981年 | 21篇 |
1980年 | 19篇 |
1979年 | 16篇 |
1978年 | 12篇 |
1977年 | 8篇 |
1976年 | 9篇 |
1975年 | 10篇 |
1973年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
1.
2.
Vincenza Granata Roberta Fusco Francesco Izzo Sergio Venanzio Setola Michele Coppola Roberta Grassi Alfonso Reginelli Salvatore Cappabianca Roberto Grassi Antonella Petrillo 《Radiology and oncology》2021,55(2):121
BackgroundCOVID-19 infection is particularly aggressive in frail patients, as cancer patients. Therefore, the more suitable management of the oncological patient requires a multidisciplinary assessment, to identify which patients should be treated, as inpatients or outpatients, and which treatments can be procrastinated.ConclusionsThe role of radiologist is crucial, and, all cancer patients who need an imaging evaluation will need to be studied, using the most appropriate imaging tools related to the clinical question and paying a special attention to preserve public health. Guidelines are necessary in the correct organization of a radiology unit to manage patients with suspected or confirmed COVID-19 infection, and whenever possible, a satellite radiography center with dedicated equipment should be used to decrease the transmission risk.Key words: COVID-19 infection, cancer patients, diagnostic unit, management, guideline 相似文献
3.
4.
5.
6.
Ester Orlandi MD Stefano Cavalieri MD Roberta Granata MD Piero Nicolai MD Paolo Castelnuovo MD Cesare Piazza MD Alberto Schreiber MD Mario Turri-Zanoni MD Pasquale Quattrone MD Rosalba Miceli MD Gabriele Infante PhD Fausto Sessa MD Carla Facco MD Giuseppina Calareso MD Nicola Alessandro Iacovelli MD Davide Mattavelli MD Alberto Paderno MD Carlo Resteghini MD Laura Deborah Locati MD Lisa Licitra MD Paolo Bossi MD 《The Laryngoscope》2020,130(4):857-865
7.
Simonetta Viviani Arabella Mazzocchi Chiara Pavoni Francesca Taverna Andrea Rossi Caterina Patti Alessandra Romano Livio Trentin Roberto Sorasio Anna Guidetti Daniela Gottardi Corrado Tarella Michele Cimminiello Roberta Zanotti Lucia Farina Andrés José Maria Ferreri Marina Galbiati Paolo Corradini Alessandro Massimo Gianni Andrea Gallamini Alessandro Rambaldi 《Hematological oncology》2020,38(4):501-508
Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation-regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET-driven trial (#NCT00795613). In 266 patients with available serum samples, who have agreed to participate in a sub-study for assessment of the role of TARC monitoring, serum TARC levels were measured at baseline and at time of PET-2 by commercially available ELISA test kits. The primary end-point was to evaluate the association between TARC after 2 ABVD cycles and PFS. Median TARC-2 values were significantly higher in PET-2-positive patients compared to PET-2-negative patients (P = .001), and in patients with treatment failure compared to those in continuous CR (P = .01). The 4-year PFS significantly differed between patients with TARC-2 >800 pg/mL vs ≤800 pg/mL (64% vs 86%, P = .0001). Moreover, among PET-2-negative patients, elevated TARC-2 identified those with a worse prognosis (74% vs 89%; P = .01). In multivariable analysis, TARC-2 >800 pg/mL was a significant independent predictor of PFS in the whole study population (HR 2.39, P = .004) and among the PET-2-negative patients (HR 2.49, P = .02). In conclusion, our results indicate that TARC-2 serum levels above 800 pg/mL suggest the need for a stringent follow-up in PET-2-negative patients, and the evaluation of new drugs in PET-2-positive, who will likely fail to respond to intensification with escalated BEACOPP. 相似文献
8.
9.
10.
Rosa Della Monica Mariella Cuomo Roberta Visconti Annabella di Mauro Michela Buonaiuto Davide Costabile Giulia De Riso Teodolinda Di Risi Elia Guadagno Roberto Tafuto Sabrina Lamia Alessandro Ottaiano Paolo Cappabianca Maria Laura Del Basso de Caro Fabiana Tatangelo Juergen Hench Stephan Frank Salvatore Tafuto Lorenzo Chiariotti 《Oncology research》2020,28(9):837-845
Unresectable neuroendocrine neoplasms (NENs) often poorly respond to standard therapeutic approaches.
Alkylating agents, in particular temozolomide, commonly used to treat high-grade brain tumors including glioblastomas, have recently been tested in advanced or metastatic NENs, where they showed promising response
rates. In glioblastomas, prediction of response to temozolomide is based on the assessment of the methylation
status of the MGMT gene, as its product, O6
-methylguanine-DNA methyltransferase, may counteract the damaging effects of the alkylating agent. However, in NENs, such a biomarker has not been validated yet. Thus, we
have investigated MGMT methylation in 42 NENs of different grades and from various sites of origin by two
different approaches: in contrast to methylation-specific PCR (MSP), which is commonly used in glioblastoma
management, amplicon bisulfite sequencing (ABS) is based on high-resolution, next-generation sequencing
and interrogates several additional CpG sites compared to those covered by MSP. Overall, we found MGMT
methylation in 74% (31/42) of the NENs investigated. A higher methylation degree was observed in welldifferentiated tumors and in tumors originating in the gastrointestinal tract. Comparing MSP and ABS results,
we demonstrate that the region analyzed by the MSP test is sufficiently informative of the MGMT methylation
status in NENs, suggesting that this predictive parameter could routinely be interrogated also in NENs. 相似文献